Search clinical trials for: BI201335 24W

Total 932 results

Boehringer Ingelheim

Completed

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Hepatitis C, Chronic

United States, Brazil, France, Germany, Italy, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

Hepatitis C

United States, Canada, Korea, Republic of, Puerto Rico, Taiwan
Boehringer Ingelheim

Completed

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

Hepatitis C, Chronic

United States, France, Germany, Spain
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

Hepatitis C

Germany
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Boehringer Ingelheim

Completed

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

Liver Cirrhosis | Hepatitis C

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy
Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
Boehringer Ingelheim

Completed

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Hepatitis C

United States, Austria, Belgium, Canada, France, Germany, Japan, Korea, Republic of, Portugal, Romania, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom
Boehringer Ingelheim

Terminated

Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Withdrawn

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

Hepatitis C, Chronic
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Healthy
Gesynta Pharma AB
CTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden AB

Completed

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Pharmacokinetic

Sweden
Iran Hepatitis Network
Baqiyatallah Research Center for Gastroenterology and Liver Diseases

Unknown

Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients (HepCC-2)

Hepatitis C
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (SIGA-246-002)

Healthy

United States
The University of Texas Health Science Center,...
National Institute on Disability, Independent Living, and Rehabilitation...

Recruiting

A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 3)

Pain Management

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Hepatitis C

Austria, Belgium, France, Germany, Japan, Portugal, Romania, Russian Federation, Spain, Switzerland, United Kingdom
Johann Wolfgang Goethe University Hospital

Completed

Comparison of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil and a Nitinol Guide Wire

Other Specified Diseases of Biliary Tract

Germany
SIGA Technologies
National Institutes of Health (NIH)

Completed

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 (246-Safety)

Orthopoxviral Disease

United States
Aprea Therapeutics

Completed

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Prostatic Neoplasms | Hematologic Neoplasms

Sweden
Healthpoint

Unknown

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

Venous Leg Ulcer

United States, Canada
Boehringer Ingelheim

Completed

Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV

Diabetes Mellitus, Type 2

Japan
Manchester University NHS Foundation Trust

Completed

Comparing the Effectiveness of a Safety Intravenous Cannula With a Standard Intravenous Cannula in Neonates (LittleReed)

Preterm Infant

United Kingdom
InnoCare Pharma Inc.

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies

Mature B-cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Hematological Malignancies

China
Healthpoint

Completed

Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds

Normal Female Volunteers

United States
Healthpoint

Terminated

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers (MOA 034)

Venous Leg Ulcers

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
SIGA Technologies
National Institutes of Health (NIH)

Completed

Phase I Trial of an Investigational Small Pox Medication

Smallpox | Monkey Pox | Orthopoxviral Disease

United States
University Hospital, Rouen

Not yet recruiting

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease (ETERNAL-PKD)

Kidney Diseases
Aristotle University Of Thessaloniki

Completed

Cardiovascular Responses to Spartathlon Running (Spartathlon)

Disorder Heart

Greece
Gesynta Pharma AB
Ergomed

Completed

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Systemic Sclerosis

United Kingdom, Poland, Belgium, Netherlands
Gruppo Oncologico del Nord-Ovest

Completed

NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN (NIVACTOR)

Squamous Cell Carcinoma of Head and Neck

Italy
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematologic Malignancies

China
Natalia A. Rivera García
cic bioGune

Completed

Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques (SLE)

Lupus Erythematosus, Systemic | Lupus Nephritis

Spain
Millennium Pharmaceuticals, Inc.

Terminated

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Advanced Malignant Solid Tumors

United States
Healthpoint

Terminated

Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

Ulcer | Venous Ulcer | Venous Stasis Ulcer

Germany, Poland, Belgium, Czech Republic, Hungary
RemeGen Co., Ltd.

Recruiting

A Study of Telitacicept in Lupus Nephritis

Lupus Nephritis

China

3

Subscribe